SCHEMBL6967576

SCHEMBL6967576

O=C1Nc2cccc(I)c2/C1=C/c1ccc[nH]1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 11/20 0.72
KDR P35968 5/20 0.72
PDGFRB P09619 5/20 0.62
TLK2 Q86UE8 5/20 0.62
RET P07949 4/20 0.62
FLT3 P36888 4/20 0.62
JAK3 P52333 3/20 0.62
FLT1 P17948 2/20 0.62
ALK Q9UM73 2/20 0.62
SYK P43405 1/20 0.62
ATM Q13315 1/20 0.62
CHEK1 O14757 1/20 0.62
AURKA O14965 1/20 0.62
DAPK3 O43293 1/20 0.62
PRKD3 O94806 1/20 0.62
MAP4K4 O95819 1/20 0.62
NTRK1 P04629 1/20 0.62
LCK P06239 1/20 0.62
FYN P06241 1/20 0.62
CSF1R P07333 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6967581 1.00 PDPK1 (0.72) PDPK1KDRPDGFRBTLK2RET
SCHEMBL6965050 0.85 PDPK1 (0.72) PDPK1KDRPDGFRBTLK2RET
SCHEMBL6965045 0.85 PDPK1 (0.72) PDPK1KDRPDGFRBTLK2RET
SCHEMBL5728466 0.84 PDPK1 (1.00) PDPK1KDRPDGFRBTLK2RET
SCHEMBL5727775 0.84 PDPK1 (0.75) PDPK1KDRPDGFRBTLK2RET
SCHEMBL5728470 0.84 PDPK1 (1.00) PDPK1KDRPDGFRBTLK2RET
SCHEMBL5727772 0.84 PDPK1 (0.75) PDPK1KDRPDGFRBTLK2RET
SCHEMBL5728634 0.84 PDPK1 (1.00) PDPK1KDRPDGFRBTLK2RET
SCHEMBL5728638 0.84 PDPK1 (1.00) PDPK1KDRPDGFRBTLK2RET
SCHEMBL6970332 0.82 PDPK1 (0.60) PDPK1KDRPDGFRBTLK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1149093-A1 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP claimed
US-6307056-B1 INHIBIT OR MODULATE PROTEIN KINASES, IN PARTICULAR JNK PROTEIN KINASES. HOFFMAN-LA ROCHE INC. 2001-10-23 US claimed
WO-2000035909-A1 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO claimed
US-8748601-B2 Selective serine/threonine kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-10 US disclosed
US-8748601-B2 Selective serine/threonine kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-06-10 US disclosed
US-8034821-B2 Selective serine/threonine kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-11 US disclosed
US-8034821-B2 Selective serine/threonine kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-11 US disclosed
US-20100256171-A1 SELECTIVE SERINE/THREONINE KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-07 US disclosed
US-20100256171-A1 SELECTIVE SERINE/THREONINE KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-07 US disclosed
US-20090221614-A1 SELECTIVE SERINE/THREONINE KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (CA) 2009-09-03 US disclosed
US-20090221614-A1 SELECTIVE SERINE/THREONINE KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (CA) 2009-09-03 US disclosed
EP-1149092-A2 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
EP-1149093-A1 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
US-6307056-B1 INHIBIT OR MODULATE PROTEIN KINASES, IN PARTICULAR JNK PROTEIN KINASES. HOFFMAN-LA ROCHE INC. 2001-10-23 US disclosed
US-6303793-B1 INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2001-10-16 US disclosed
US-6252086-B1 CYCLIN-DEPENDENT KINASES INHIBITORS; ANTICANCER AGENTS HOFFMANN-LA ROCHE INC. 2001-06-26 US disclosed
US-6130239-A INHIBIT CYCLIN-DEPENDENT KINASES HOFFMANN-LA ROCHE INC. (US) 2000-10-10 US disclosed
WO-2000035906-A2 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed
WO-2000035909-A1 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed
WO-2000035908-A1 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221614-A1 SELECTIVE SERINE/THREONINE KINASE INHIBITORS DSTYK, TTK, SBK1 PDPK1 9/4885KDR 1000/4885PDGFRB 1614/4885
US-20100256171-A1 SELECTIVE SERINE/THREONINE KINASE INHIBITORS DSTYK, TTK, SBK1 PDPK1 9/4885KDR 1000/4885PDGFRB 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.